Eyenovia, Inc. announced the U.S. launch and commercial availability of clobetasol propionate ophthalmic suspension 0.05% on September 26, 2024. This FDA-approved product is indicated for the treatment of post-operative inflammation and pain following ocular surgery.
Clobetasol is the first new ophthalmic steroid to be approved in over 15 years, offering a convenient twice-a-day dosing regimen. The company has designed its distribution model to minimize complications from insurance, aiming to generate strong interest among eye doctors.
Market research commissioned by Eyenovia indicated a strong level of interest from ophthalmic surgeons in Clobetasol, based on their review of its prescribing information. This launch represents a significant milestone for the company and a meaningful advancement in ocular surgery.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.